Azenta's Third Quarter: A Mixed Bag of Gains
When it comes down to the nitty-gritty, Azenta, Inc. (NASDAQ:AZTA) is navigating some choppy waters yet making headway. The latest third-quarter results show revenue from continuing operations climbing 12% year over year, reaching $161 million. Not too shabby in a market that's been as volatile as an old jalopy on a gravel road.
Discontinued Ops and Strategic Moves
Splitting hairs here, but it's crucial to mention the sale of B Medical Systems, which wrapped up on July 1, 2026. This move shifts some numbers around as those figures are now swept under 'discontinued operations.' Management might tout it as streamlining, but it's worth keeping an eye on how this influences overall performance.
Breaking Down Segment Performance
The Sample Management Solutions segment is holding its ground with a 14% year-over-year growth. Organic growth hit 9%, despite a slight dent from lower automated store sales. The Multiomics business isn't lagging, either, boasting a 10% rise in revenue on the back of next-gen sequencing success, albeit tempered by a dip in Sanger revenue.
Cracking the Financial Nut
GAAP and Non-GAAP Perspective
Operating losses for continuing operations hit $4.2 million, with the gross margin sliding a bit to 44.9%. Fewer sales in certain areas and some costly fixes in Automated Stores didn't help, but operating leverage cushioned the fall.
"Despite an uneven and challenging market backdrop, our third quarter results exceeded our expectations," said CEO John Marotta.
Adjusted EBITDA is up at $18.5 million, but mind you, margins are under pressure, slipping to 11.4%.
The Earnings Picture
Diluted EPS from continuing operations is in the red at a loss of $0.03, showing slight jitter compared to previous results. On the brighter side, diluted EPS from all operations flipped to a gain of $0.05 from a steep negative in 2025. Non-GAAP diluted EPS clings to stability at $0.16.
Cash Talk and Share Buybacks
The cash pile's sitting pretty at $529 million as of June, though free cash flow takes a hit, diving $5 million into the negatives. The ongoing share buyback program swallowed 2.3 million shares for $50 million, a strategic move under the 2025 plan.
Looking Ahead: Guidance and Strategy
With the fiscal year closing in, Azenta's revised guidance foresees revenue in the range of $613 to $618 million. But here's the kicker: organic revenue could stay flat or edge up a mere 1%, a slight upgrade from earlier forecasts. Adjusted EBITDA projections span $59 to $62 million.
- Revenue outlook suggests declines in the next quarter, but there's strategic optimism fueling the broader year.
- The share repurchase program continues to demonstrate confidence, with funds allocated up to $250 million through 2028.
Final Take
Azenta is in the throes of a classic corporate tightrope walk: balancing ambitious growth plans with real-world hitches—cost overruns and restructuring mixed in, for example. But they're not sitting on their hands, whipping up strategic plans meant to hurdle over their current speed bumps.
Investors eyeing NASDAQ:AZTA need to remember: in this game, recognizing nuances between a flashy headline growth rate and the underlying operational grind is crucial. Buckle up; this ride ain't over yet.
